Table 3.
Disease response and patient outcomes in patients who completed the alloHCT (n = 102)
| At autoHCT | n | At alloHCT | n | Best response after alloHCT | n | Relapse/progression |
Nonrelapse deaths |
Pts alive in remission |
|---|---|---|---|---|---|---|---|---|
| n (mo) | n (mo) | n (mo) | ||||||
| CR | 7 | CR | 7 | CR | 7 | 3 (40, 48, 73) | 1 (3) | 3 (57,75, 92) |
| VGPR | 19 | CR | 6 | CR | 6 | 2 (25, 77) | 2 (3, 7) | 2 (55, 89) |
| VGPR | 13 | CR | 13 | 6 (median 26, range 16-38) | 1 (47) | 6 (median 47, range 30-83) | ||
| PR | 50 | CR | 4 | CR | 4 | 2 (11, 11) | 2 (47, 85) | |
| VGPR | 10 | CR | 6 | 2 (14, 16) | 4 (median 81, range 35-102) | |||
| VGPR | 4 | 2 (56, 66) | 2 (5,77) | |||||
| PR | 36 | PR | 14 | 7 (median 17, range 1-48) | 5 (median 7, range 3-13) | 2 (33, 49) | ||
| VGPR | 5 | 3 (24, 72, 79) | 1 (4) | 1 (30) | ||||
| CR | 17 | 8 (median 42, range 14-78) | 9 (median 86, range 30-103) | |||||
| RD | 16 | CR | 1 | CR | 1 | 1 (5) | ||
| VGPR | 1 | CR | 1 | 1 (15) | ||||
| PR | 3 | CR | 1 | 1 (25) | ||||
| PR | 2 | 1 (14) | 1 (47) | |||||
| RD | 11 | CR | 4 | 4 (13, 16, 21, 37) | ||||
| VGPR | 1 | 1 (48) | ||||||
| PR | 2 | 2 (9, 13) | ||||||
| SD | 4 | 4 (2, 5, 13, 19) | ||||||
| PD | 10 | CR | 1 | CR | 1 | 1 (18) | ||
| PR | 2 | CR | 2 | 1 (57) | 1 (76) | |||
| RD | 5 | CR | 3 | 2 (32, 64) | 1 (76) | |||
| VGPR | 1 | 1 (74) | ||||||
| PR | 1 | 1 (23) | ||||||
| PD | 2 | PD | 2 | 1 (5) | 1(3) |
Pts indicates patients; RD, refractory disease; SD, stable disease; and PD progressive disease.